Korro Bio (KRRO) Price & Analysis

Compare

547 Followers

KRRO Stock Chart & Stats

$8.21

-$1.03(-2.68%)

At close: Jan 08 4:00 PM EST

$8.21

-$1.03(-2.68%)

Day’s Range― - ―

52-Week Range$5.20 - $55.89

Previous CloseN/A

Volume28.02K

Average Volume (3M)734.66K

Market Cap

$74.21M

Enterprise Value$400.95M

Total Cash (Recent Filing)$93.48M

Total Debt (Recent Filing)$44.67M

Price to Earnings (P/E)―

Beta2.47

Next Earnings

Mar 31, 2026

EPS Estimate

-2.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.92

Shares Outstanding9,417,295

10 Day Avg. Volume1,808,258

30 Day Avg. Volume734,659

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)2.12

Price to Sales (P/S)149.54

P/FCF Ratio-4.36

Enterprise Value/Market Cap5.40

Enterprise Value/Revenue54.40

Enterprise Value/Gross Profit54.40

Enterprise Value/Ebitda-4.53

Forecast

1Y Price Target

$56.60

Price Target Upside589.40% Upside

Rating ConsensusHold

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Bears Say

Clinical TrialsKorro announced KRRO-110 did not reach target levels of functional AAT following a single administration in AATD patients.

Management DecisionsManagement said that due to the risk/benefit profile, they are unlikely to continue clinical development of '110.

Strategic ShiftsKorro is abandoning the current KRRO-110 formulation and pivoting to a GalNAc-conjugated AATD construct, with a new candidate not expected until 1H26—placing the program clearly behind competitors.

Korro Bio News

Korro Bio Enhances Executive Compensation and Retention Incentives

Korro Bio ( ($KRRO) ) has shared an announcement. On December 15, 2025, Korro Bio, Inc. amended and...

5d ago

KRRO

Korro Bio’s Strategic Shift Amidst Clinical Setbacks and Financial Stability Justifies Hold Rating

JonesTrading analyst Catherine Novack has maintained their neutral stance on KRRO stock, giving a Hold rating yesterday. Catherine...

1M ago

KRRO

JonesResearch downgrades Korro Bio on KRRO-110 failure

JonesResearch downgraded Korro Bio (KRRO) to Hold from Buy without a price target after the company announced KRRO-110...

1M ago

KRRO

Korro Bio downgraded to Hold from Buy at JonesResearch

JonesResearch downgraded Korro Bio (KRRO) to Hold from Buy. Published first on TheFly – the ultimate source for...

1M ago

KRRO

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Traders will find all of the latest stock market stories worth reading about on Thursday in our daily wrap-up. ...

1M ago

AMD

DIA

Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

AZO

BMY

Why Is Korro Bio Stock (KRRO) Down Today?

Korro Bio stock dove after the company revealed a failed clinical trial and announced layoffs. ...

1M ago

KRRO

Korro Bio downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Korro Bio (KRRO) to Perform from Outperform. Published first on TheFly – the ultimate source for...

1M ago

KRRO

Korro failure strengthens Wave Life Sciences position, says Jefferies

Korro Bio’s (KRRO) lead asset KRRO-110 failing to produce protective levels of corrected protein in a Phase 1/2...

1M ago

WVE

KRRO

Korro Bio downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi downgraded Korro Bio (KRRO) to Neutral from Overweight with a price target of...

1M ago

KRRO

Korro Bio downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor downgraded Korro Bio (KRRO) to Neutral from Buy without a price target The...

1M ago

KRRO

Korro Bio downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital analyst Luca Issi downgraded Korro Bio (KRRO) to Sector Perform from Outperform with a price target...

1M ago

KRRO

Korro Bio downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Korro Bio (KRRO) to Market Perform from Outperform without a price target The disappointing data...

1M ago

KRRO

Korro Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald last night downgraded Korro Bio (KRRO) to Neutral from Overweight without a price target after the...

1M ago

KRRO

KRRO FAQ

What was Korro Bio’s price range in the past 12 months?

Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.

What is Korro Bio’s market cap?

Korro Bio’s market cap is $74.21M.

When is Korro Bio’s upcoming earnings report date?

Korro Bio’s upcoming earnings report date is Mar 31, 2026 which is in 98 days.

How were Korro Bio’s earnings last quarter?

Korro Bio released its earnings results on Nov 12, 2025. The company reported -$1.92 earnings per share for the quarter, beating the consensus estimate of -$2.594 by $0.674.

Is Korro Bio overvalued?

According to Wall Street analysts Korro Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Korro Bio pay dividends?

Korro Bio does not currently pay dividends.

What is Korro Bio’s EPS estimate?

Korro Bio’s EPS estimate is -2.03.

How many shares outstanding does Korro Bio have?

Korro Bio has 9,417,295 shares outstanding.

What happened to Korro Bio’s price movement after its last earnings report?

Korro Bio reported an EPS of -$1.92 in its last earnings report, beating expectations of -$2.594. Following the earnings report the stock price went down -79.313%.

Which hedge fund is a major shareholder of Korro Bio?

Currently, no hedge funds are holding shares in KRRO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Korro Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-63.46%

Trailing 12-Months

Asset Growth

-33.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Korro Bio

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio (KRRO) Earnings & Revenues

Historic Earnings Reports

KRRO Stock 12 Month Forecast

Average Price Target

$56.60

▲(589.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","181":"$181","49.75":"$49.8","93.5":"$93.5","137.25":"$137.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,49.75,93.5,137.25,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.91,51.60923076923076,62.308461538461536,73.00769230769231,83.70692307692308,94.40615384615384,105.10538461538462,115.80461538461539,126.50384615384615,137.20307692307694,147.9023076923077,158.60153846153847,169.30076923076925,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.91,42.11692307692307,43.32384615384615,44.53076923076923,45.737692307692306,46.94461538461538,48.15153846153846,49.35846153846154,50.565384615384616,51.77230769230769,52.97923076923077,54.18615384615384,55.39307692307692,{"y":56.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.91,38.301538461538456,35.69307692307692,33.08461538461538,30.476153846153842,27.867692307692305,25.25923076923077,22.650769230769228,20.04230769230769,17.433846153846154,14.825384615384614,12.216923076923077,9.60846153846154,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.16,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >